EXOZ invizyne.com: Multiplikator forward rega marang pendapatan

Simbol resmi perusahaan eXoZymes (EXOZ)

Margins at eXoZymes Inc (EXOZ) are declining due to energy shocks and sanctions. The projected P/S ratio visualizes this volatility, where describes the current status of the metric. Rising petrochemical prices and logistics disruptions are weighing on production. High laboratory costs, coupled with a lack of scale, are creating a significant financial burden on the young biotech company.

EXOZ Invizyne Technologies: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 13.11.2026

EXOZ (Invizyne): rincian analitis lan laporan miturut indikator

- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
Analisis kabeh metrik perusahaan:eXoZymes EXOZ
Produk sing diprodhuksi eXoZymes Inc

Stable cash flow and the fulfillment of obligations by eXoZymes Inc (EXOZ) create a solid foundation for assessing the market premium for future growth. The forward price-to-sales ratio measures investor expectations regarding sales expansion rates, while the forward P/S trend helps determine whether the asset is overvalued relative to its actual business scaling potential.

Analisis pesaing

Multiplikator Forward P/S HLN (Haleon)|Kenvue Inc (KVUE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|VRNA: Multiplikator forward rega marang pendapatan|MENS (Jyong Bio) - Kapitalisasi marang prakiraan pendapatan|Ligand Pharmaceuticals (LGND) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep amneal.com (AMRX)|Multiplikator forward rega marang pendapatan PRGO|Alvotech S.A. - Rega mangsa ngarep marang pendapatan|Multiplikator forward rega marang pendapatan LQDA (Liquidia Technologies)|GLPG - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan ANI Pharmaceuticals ANIP|MNKD - Multiplikator forward rega marang pendapatan|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pacira Pharmaceuticals|ARS Pharma (SPRY) - Rasio rega marang prakiraan pendapatan|TBPH - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan AQST|SCPH: Rega forward marang dodolan|Multiplikator Forward P/S TECX|Rasio kapitalisasi marang dodolan sing dikarepake Tonix Pharma|Rasio rega marang prakiraan pendapatan China SXT Pharmaceuticals, Inc. SXTC|EPRX: Kapitalisasi marang prakiraan pendapatan|BioHarvest Sciences - Multiplikator Forward P/S|Oramed Pharmaceuticals (ORMP) - Multiplikator forward rega marang pendapatan|ENTX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep MindWalk Holdings, Inc. (HYFT)|Multiplikator forward rega marang pendapatan ABVC|Kapitalisasi marang prakiraan pendapatan CPIX (Cumberland Corp)|Rasio rega marang prakiraan pendapatan Quantum BioPharma Ltd (QNTM)|FGEN - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Telomir Pharmaceuticals, Inc. - Multiplikator forward rega marang pendapatan|RANI (Rani Therapeutics Holdings) - Rega mangsa ngarep marang pendapatan|SNYR - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan RLYB|LEXX: Multiplikator Forward P/S|pulmatrix.com - Rega forward marang dodolan|PTHL (Pheton Holdings Limited) - Multiplikator Forward P/S|Multiplikator Forward P/S Aptorum|Rasio rega marang prakiraan pendapatan Lyra Therapeutics, Inc (LYRA)|IBO (Impact BioMedical, Inc.) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan TNF Pharmaceuticals, Inc. TNFA|YCBD - Multiplikator forward rega marang pendapatan|PainReform - Multiplikator Forward P/S|CYTO - Multiplikator Forward P/S|LIPO (Lipella) - Multiplikator forward rega marang pendapatan|OptiNose Corp - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep procapsgroup.com PROC|Multiplikator forward rega marang pendapatan PTPI (Petros Pharmaceuticals, Inc.)|Rasio rega marang pendapatan sing dikarepake QLI|Multiplikator Forward P/S SLRN (ACELYRIN, Inc.)|Rega forward marang dodolan TFFP